- Home
- API vs VCRE Comparison
API vs VCRE Comparison
Compare API & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | API | VCRE |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.0M | 316.4M |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | API | VCRE |
|---|---|---|
| Price | $4.08 | $11.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 120.4K | 8.0K |
| Earning Date | 05-26-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.46 | N/A |
| Revenue Next Year | $12.87 | N/A |
| P/E Ratio | $92.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.14 | $10.47 |
| 52 Week High | $5.50 | $13.15 |
Technical Indicators
Market Signals| Indicator | API | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | N/A |
| Support Level | $4.01 | N/A |
| Resistance Level | $4.10 | N/A |
| Average True Range (ATR) | 0.11 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 17.68 | 0.00 |
Price Performance
Historical ComparisonAbout API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.